HC Wainwright Has Positive Opinion of Oculis FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $1.63 per share from a loss of $1.72, and maintained a Buy rating with a $39 price target.
• Oculis reported a quarterly loss of $0.37 per share, beating the $0.47 loss analysts expected; revenue was $0.01 million versus a $0.26 million consensus estimate.
• Analyst sentiment is broadly positive: nine analysts rate Oculis Buy and one Sell, resulting in a Moderate Buy consensus and an average price target of $38.89.

Oculis Holding AG (NASDAQ:OCS - Free Report) - Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Oculis in a research report issued on Wednesday, November 4th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($1.63) per share for the year, up from their prior forecast of ($1.72). HC Wainwright has a "Buy" rating and a $39.00 price objective on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Oculis' Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.93) EPS.

Other research analysts have also issued reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a research report on Thursday, October 15th. Guggenheim reduced their price target on Oculis to $40.00 and set a "buy" rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. decreased their price target on Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Finally, Wall Street Zen upgraded Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $38.89.

Oculis Stock Performance

Shares of Oculis stock opened at $6.83 on Friday. The stock has a market cap of $396.00 million, a price-to-earnings ratio of -3.99 and a beta of 0.67. Oculis has a twelve month low of $6.78 and a twelve month high of $34.47. The company's fifty day moving average is $9.29 and its 200 day moving average is $18.44. The company has a quick ratio of 8.35, a current ratio of 10.41 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.10. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.26 million. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.24%.

Hedge Funds Weigh In On Oculis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after acquiring an additional 5,813 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Oculis in the 3rd quarter worth about $74,000. Koshinski Asset Management Inc. bought a new position in shares of Oculis in the 1st quarter worth about $238,000. Himension Capital Singapore PTE. LTD. acquired a new position in shares of Oculis in the 1st quarter valued at about $503,000. Finally, Alps Advisors Inc. lifted its stake in shares of Oculis by 40.7% in the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company's stock valued at $762,000 after purchasing an additional 23,600 shares during the period. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.